slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
227,461-227,490 of 319,975
15
The slide uses a visual comparison framework to contrast three different drug mechanisms.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
16
This is a section divider or introductory slide for the product solution.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
17
The slide uses a four-column structure to explain the drug's mechanism, structure, preclinical results, and clinical status.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
18
The slide uses a structured comparison of four distinct disease areas to justify the market potential of the EQ101 franchise.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
19
The slide uses western blot data to demonstrate the mechanism of action difference between the competitor (Ruxolitinib) and the company's drug (EQ101).Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
20
Includes clinical trial data and visual evidence of skin improvement.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations Beat · Traction1 hit
21
Equillium | Investor Presentation Deck | 40 slidesEquillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations Beat · Traction1 hit
22
The diagram uses a circular flow/flywheel-like representation to show the disease cycle.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
23
Includes visual longitudinal study (Day 0, 14, 21) and a bar chart comparing PBS, Ruxolitinib, and EQ101.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
24
Data shows higher response rates for 4-mg dose and correlation between baseline severity and treatment efficacy.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
25
The slide uses a combination of qualitative physician sentiment and quantitative survey data to frame the problem of safety in current standard-of-care treatments.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
Includes definition of SALT score in footer.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
27
Equillium | Investor Presentation Deck | 40 slidesEquillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
28
The slide uses a four-column process flow to explain the biological rationale, mechanism, preclinical validation, and development status.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
29
The slide uses scientific citations to validate the mechanism of action (IL-21/IL-15) upstream of current therapies.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
30
Uses a clear contrast between patient count and available treatments to frame the market opportunity.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a circular process diagram to illustrate the pathology of celiac disease and provides a stack of academic paper headers as evidence.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
32
The diagram shows a circular process where inhibitors block IL-15 and IL-21 to prevent damage to gut epithelium.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
33
The slide uses a process-like flow to highlight 'reduce inflammation' as the key target, supported by logos of major pharma companies.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
34
The table categorizes competitors by mechanism (Gluten Modification, Barrier Function, Immune Tolerance, Reduce Inflammation) and lists drug names, targets, and administration routes.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
35
Equillium | Investor Presentation Deck | 40 slidesEquillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
36
The slide uses a grid of headshots for the team and a logo grid for their collective industry experience.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations Beat · Team1 hit
37
The slide uses a timeline-based bar chart to represent the duration of IP protection and exclusivity for various therapeutic assets.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
38
Equillium | Investor Presentation Deck | 40 slidesEquillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
39
The slide combines clinical development timelines with financial runway projections.Equillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations Loop · Why Now1 hit
40
Equillium | Investor Presentation Deck | 40 slidesEquillium | Investor Presentation Deck | 40 slides · Equillium
Pitch deck Investor relations 1 hit
01
Essity | Investor Presentation Deck | 27 slidesEssity | Investor Presentation Deck | 27 slides · Essity
Conference presentation Investor relations 1 hit
02
Essity | Investor Presentation Deck | 27 slidesEssity | Investor Presentation Deck | 27 slides · Essity
Conference presentation Investor relations 1 hit
03
The slide serves as an introduction to the company's mission and scale.Essity | Investor Presentation Deck | 27 slides · Essity
Conference presentation Investor relations 1 hit
04
The slide uses a high-contrast pink background with product photography on the right side.Essity | Investor Presentation Deck | 27 slides · Essity
Conference presentation Investor relations 1 hit